Attovia Therapeutics, Inc. (ATTO)
NasdaqGM: ATTO
· 实时价格 · USD
25.55
+1.35 (5.58%)
收盘价： Sep 04, 2026, 3:59 PM
25.56
+0.04%
盘后: 7:36 PM
股价、关键数字和最新消息，都在这一页。
Attovia Therapeutics, Inc.（ATTO）股价、分析与数据
5.58% (1D)
| 买价 | n/a |
| 市值 | 1.17B |
| 营收（TTM） | 1.8M |
| 净利润（TTM） | -70.1M |
| 0.00 | |
| -1.64 | |
| n/a | |
| -10.74 | |
| 市净率（TTM） | -0.92 |
| 市销率（TTM） | 647.99 |
| 财报日期 | Nov 11, 2026 |
| 卖价 | n/a |
| 成交量 | 311,049 |
| 20日均量 | 463,569 |
| 开盘价 | 24.44 |
| 前收盘价 | 24.20 |
| 日内区间 | 24.44 - 27.66 |
| 52周区间 | 16.15 - 27.66 |
| 分析师 | 强烈<br>买入 |
| 目标价 | 45 (76.13%) |
| 分红 | n/a |
| 除息日 | n/a |
关于 ATTO
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch ...
公司完整简介财报意外
Attovia Therapeutics 已于 Sep 2, 2026 发布季度财报：
- 营收为 $0 低于预期 $0, ， NaN% 同比增长.
- 每股收益为 -4.88 低于预期 -0.27, ， -Infinity% 同比下滑.
第 1 页，共 2 页